[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"neurological-conditions\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:neurological-conditions":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,42,80,104,135,164,204,225],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100122228","neurosciences-research-repository-100122228",false,"NCT00857922","Neurosciences Research Repository","NRR","Inclusion Criteria:\n\n1. Neurosurgical patient (primary or consulting); patients\\\u003C18 includes residual tissue only, no blood samples.\n2. Family members of specific vascular, trauma, brain tumor and functional disorder cohorts (will be identified in future addendums to this repository)\n\nExclusion Criteria:\n\n1\\. Inability to obtain informed consent",true,"ALL","0 Years",{"count":20,"type":21},15000,"ESTIMATED","OBSERVATIONAL","In order to expand neuroscience research and move laboratory advances to patients, there is a need to integrate reliable clinical data with biologic information from patient tissue specimens. The Neuroscience Research Repository (NRR) seeks to meet this need. The NRR is a prospective database and sample bank created to collect information and samples for current and future neuroscience research. The objective of this NRR is to develop a data and sample repository for study of neurological conditions. A repository utilizing standardized electronic health data and samples collected in a uniform manner serves to foster the ability to perform research on current and future projects. Samples and data for clinical, genomic and proteomic analysis will be provided to optimize their value for neuroscience research.\n\nThe NRR will enroll patients and collect clinically recorded longitudinal data for as long as they are followed by the Neurosurgery service and up to an additional 5 years after being released from care. Patients will be enrolled on admission to the service and samples will be taken at three time points: Time One, within 24 hours of event (preferably first blood draw); Time Two, within 48 hours of event; and Time Three, time of any residual tissue availability. Family members of select groups of patients will also be approached for enrollment.\n\nSamples and data will be labeled with a study code to maintain confidentiality. Samples and data will be maintained in secure, limited access environments with back-up\u002Fredundancy procedures in place. Sample inventory will be maintained with a bar-coding system. A duty to warn clause will be included in the consent as will the determination of willingness to be re-contacted for future research. Time of sample acquisition to time of sample processing will be documented for quality control purposes. Freezers will be monitored for temperature stability. Recipient investigators will be requested to provide feedback on sample quality. Samples will be distributed to neuroscience investigators after approval from the Neurosurgery Scientific Review Committee - Dissemination Review Committee and the Committee for the Protection of Human Subjects (CPHS).",[25],"Neurological Conditions",[27,28],"Neurological","Neurosurgical","RECRUITING","2026-06-12",{"date":32,"type":33},"2026-06-16","ACTUAL",{"date":35,"type":33},"2009-03",{"date":37,"type":21},"2030-08",{"name":39,"class":40},"The University of Texas Health Science Center, Houston","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":17,"minAge":49,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":60,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":41},"100643406","3d-hand-orthosis-trial-100643406","NCT07633821","3D Hand Orthosis Trial","Cost-effectiveness of 3D-printed Hand Orthoses for Activities of Daily Living in Chronic Hand Conditions","Inclusion Criteria:\n\n* Diagnosed with a chronic, stable hand condition due to a neurological disorder, musculoskeletal disorder, neuromuscular disease or injury;\n* Minimum age of 18 years;\n* Indicated for a first or repeat prescription of a circular thumb, wrist or wrist-thumb orthosis for permanent use for improving ADL performance.\n\nExclusion Criteria:\n\n* Indicated for an orthosis for a non-functional hand;\n* Insufficient mastery of the Dutch language.","18 Years",{"count":51,"type":21},100,"INTERVENTIONAL",[54],"NA","In people with chronic hand conditions, hand orthoses are frequently prescribed to improve performance in activities of daily living (ADL). Conventional hand orthoses are custom-made on a plaster cast of the hand, a process that is time-consuming and labor-intensive. It has been demonstrated that the production time of manufacturing hand orthoses can be reduced by using 3-dimensional scanning and printing (i.e. 3D-printed hand orthosis), offering a promising cost-effective alternative to conventional hand orthoses. The current study builds on a previously conducted feasibility study, which demonstrated comparable effects of 3D-printed and conventional hand orthoses on ADL performance, hand function, and quality of life in people with chronic hand conditions. User satisfaction and production time favored the 3D-printed orthoses. However, to date only small and self-controlled studies have investigated the effects of 3D-printed versus conventional hand orthoses for permanent use on ADL performance and orthosis satisfaction in chronic hand conditions. Evidence from randomized controlled trials and data on the cost-effectiveness are lacking. The aims of this study are:\n\n1. To determine whether treatment with 3D-printed hand orthoses is non-inferior compared to treatment with conventional hand orthoses in terms of ADL performance, hand function, pain, quality of life and functional status in individuals with chronic hand conditions.\n2. To assess whether treatment with 3D-printed hand orthoses results in greater patient satisfaction compared to treatment with conventional hand orthoses.\n3. To assess the cost-effectiveness of treatment with 3D-printed hand orthoses compared to treatment with conventional hand orthoses.",[57,25,58,59],"Hand Injuries and Disorders","Neuromuscular Diseases (NMD)","Musculoskeletal Conditions (e.g., Tendinitis, Capsulitis)",[61,62,63,64,65,66,67,68,69],"Orthotic Devices","Cost-Effectiveness Analysis","Hand","Printing, Three-Dimensional","Activities of Daily Living","Rehabilitation","Quality of Life","Non-Inferiority Trial","Patient Satisfaction","NOT_YET_RECRUITING","2026-06-05",{"date":73,"type":33},"2026-06-08",{"date":75,"type":21},"2026-06",{"date":77,"type":21},"2030-09",{"name":79,"class":40},"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)",{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":4,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":17,"minAge":49,"maxAge":4,"enrollmentInfo":87,"targetDuration":4,"studyType":52,"phases":89,"briefSummary":91,"conditions":92,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":4},"100639554","phase-1-olfactory-cell-transplantation-and-intensive-rehabilitation-to-repair-chronic-spinal-cord-injury-100639554","NCT07596563","Olfactory Cell Transplantation and Intensive Rehabilitation to Repair Chronic Spinal Cord Injury","Safety, Feasibility, Efficacy of Olfactory Cell Transplantation Therapy Combined With Intensive Exercise Rehabilitation to Repair Chronic Traumatic Spinal Cord Injury.","Inclusion\u002Fexclusion criteria for participants have been determined in consultation with medical and rehabilitation specialists including a clinician with lived experience of SCI.\n\nInclusion Criteria\n\nParticipants are eligible to be included in the trial only if all the following criteria apply:\n\n1. Have sustained an acquired spinal cord injury a minimum of 4 months prior to consent and have completed their primary rehabilitation;\n2. Have a stable neurological level and functional ability of more than two months in duration;\n3. Are over 18 years and able to give informed consent;\n4. Are AIS A, B or low functioning C (more than 75% of key muscles have a power grade \\\u003C3) as per the International Standards for Neurological Classification of spinal cord injury, and documented by an ISNCSCI\u002FASIA exam performed by a qualified practitioner within the last six months;\n5. Have a thoracic injury or lower cervical (C5-C8) injury;\n6. Are able and willing to attend an exercise program five times per week for the duration of the priming rehabilitation program, with allowance for two weeks recreational leave;\n7. Are able and willing to attend an exercise program five times per week for at least 12 weeks of the regenerative rehabilitation program and then at least three days per week for the remaining 20 weeks, with allowance for four weeks recreational leave;\n8. Are considered by their general practitioner or specialist medical consultant to be fit to receive the cell transplantation and undertake the exercise program (documented approval by general practitioner required).\n\nExclusion Criteria\n\nParticipants are excluded from the trial if any of the following criteria apply:\n\n1. Have a high cervical (C1-C4) injury (excluded due to respiratory risk);\n2. Have significant concomitant central nervous system, peripheral nervous system or musculoskeletal system injuries or disorders limiting their ability to exercise;\n3. Have had recent major trauma or surgery within the last 4 months;\n4. Have an existing stage 3 or 4 pressure ulcer according to the National Pressure Ulcer Advisory Panel classification;\n5. Have endocrinopathy or metabolic disorders of the bone that lead to increased risk of injury from the intense long-term exercise therapy, including but not limited to pathological fractures, Paget's disease, lytic or renal bone disease, and senile osteoporosis;\n6. Have a medical history of exposure to medication(s) known to adversely affect mineral or bone metabolism;\n7. Have significant impairment or disability, including physical, neurological or psychological impairments, in addition to the spinal cord injury;\n8. Have a history of long bone fracture incompletely healed;\n9. Have extensive fixed contractures in the upper or lower limbs;\n10. Have severe spasticity that interferes with ability to exercise;\n11. Have uncontrolled neuropathic pain;\n12. Have autonomic dysreflexia without a management plan;\n13. Have a known allergic sensitivity to antibiotics used in the nerve bridge production process;\n14. Do not have adequate transport options to attend the rehabilitation sessions or the assessments;\n15. Are unable to attend the pre-intervention assessments and the follow-up assessments;\n16. Have any contraindications to FES, MRI, X-ray and other study procedures, such as a cardiac pacemaker, epilepsy, lower limb fracture or pregnancy;\n17. Have any other serious medical condition including but not limited to malignancies, auto-immune disorders (requiring continuous pharmaceutical management), psychiatric, behavioural or drug dependency problems, which are likely to influence the participant's ability to cooperate or, in the opinion of the trial investigator, would prevent adherence to the protocol;\n18. Have symptomatic, radiologically demonstrated, or provocatively demonstrated ischaemic heart disease;\n19. Have current thromboembolic disease;\n20. Are using illicit drugs;\n21. Are participating in other clinical trials (including medication, therapeutic interventions and alternative therapies).\n22. Are unable to tolerate expected exercise load.\n23. Are unable to comply with the assessment regime (such as having claustrophobia which prevents MRI procedures being conducted);\n24. Are unable to demonstrate that they have adequate social\u002Ffamily\u002Fcarer support at home to enable their participation throughout the trial.\n25. Evidence of an active infection, confirmed by testing, of a type that would pose an unacceptable risk for the viability of the nasal biopsy, the cell production, or the nerve bridge production.",{"count":88,"type":21},30,[90],"PHASE1","This is a randomised, blinded and controlled Phase I trial to measure the safety, feasibility and efficacy of a combined cell transplantation and intensive rehabilitation intervention to treat spinal cord injury. The trial aims to examine whether transplantation of olfactory cell nerve bridges combined with intensive rehabilitation is safe and feasible for people living with chronic spinal cord injury in Australia, and whether the intervention improves structural integrity of the spinal cord, functional recovery, overall health, and social wellbeing.\n\nFor the olfactory cell nerve bridge transplant, cells from inside the patient's own nose will be purified and engrafted as 3D cellular nerve bridges. Participants will receive a dose that is dependent on the size of the accessible space within the injury site of the spinal cord with up to 60 million cells being engrafted. The surgery for the transplantation will be performed by a neurosurgeon in which the spinal cord will be exposed to enable the nerve bridges to be placed into the injury site. The duration of the procedure will be 3-4 hours. Surgical notes will be used to monitor adherence to the protocol.\n\nFor intensive exercise rehabilitation, the intervention will be supervised and provided by physiotherapists and exercise physiologists at a for-purpose neurorehabilitation facility. The mode of administration will be one-on-one sessions. The 12- and 32-week rehabilitation programs will consist of up to 3 hours per day at the rehabilitation service providers, for 5 days per week. Participants will attend the provider that is within their geographical area. Over each week, sessions will involve a range and mix of activities which could include, but are not limited to, standing, gait training, upper limb strength, trunk stability\u002Fcore strength, and aerobic training. Throughout the trial, logs of exercise activities will be completed by the participants and staff at the neurorehabilitation gyms. Rehabilitation will start from day 1 of the priming rehabilitation (PR) program and go for 12 weeks, then surgery and cell transplantation will occur at week 1 of the cell transplantation surgery and recover program which is 2 weeks post conclusion of Priming Rehabilitation (PR), followed by 5 weeks of recovery.\n\nRehabilitation is for 32 weeks starting 6 weeks post transplant surgery. Regenerative rehabilitation program is from weeks 1-32 of the regenerative rehabilitation (RR) program.\n\nIf nerve bridge production fails for whatever reason in the weeks prior to surgery, this will start an extension\u002Fcontingency\u002Falternative timeline, where a new nasal biopsy will need to be taken from the participant (along with accompanying tests). The cells will be grown up over the next 4 weeks with an additional week of nerve bridge production, while the participant engages in a further five weeks of priming rehabilitation.",[93,25,94],"Spinal Cord Injury","Rehabilitation Exercise","2026-05-12",{"date":97,"type":33},"2026-05-19",{"date":99,"type":21},"2026-05-01",{"date":101,"type":21},"2031-08-01",{"name":103,"class":40},"Dr Brent McMonagle",{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":17,"minAge":111,"maxAge":112,"enrollmentInfo":113,"targetDuration":4,"studyType":52,"phases":115,"briefSummary":116,"conditions":117,"keywords":120,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":41},"100575506","iamable-implementation-and-evaluation-of-an-app-for-evidence-based-self-management-rehabilitation-strategies-100575506","NCT06773169","IAMABLE: Implementation and Evaluation of an App for Evidence-Based Self-Management Rehabilitation Strategies","IAMABLE","Inclusion Criteria:\n\n* is community-dwelling, has access to a computer or mobile device, has an email address, is able to follow directions in English, self-reports at least one of three types of prevalent chronic conditions associated with disability that frequently require rehabilitation supports (i.e., musculoskeletal, cardiovascular, and neurological conditions), responds \"somewhat easily\" or \"very easily\" to questions on the Modified Computer Proficiency Questionnaire (MCPQ-12).\n\nExclusion Criteria:\n\n* scores \\\u003C 11\u002F15 on the Montreal Cognitive Assessment (MoCA) 5-Minute Test (Version 2.1).","44 Years","75 Years",{"count":114,"type":21},50,[54],"Background: As the population gets older, a rise in chronic conditions has resulted in increased demand for rehabilitation. We developed a web-based app called IAMABLE (I am able), to share evidence-based rehabilitation strategies with people with chronic conditions. Our project will guide us to test this app's effectiveness and explore the ways that people use it.\n\nGoals, Methods, Approach: This pilot randomized controlled trial will offer people receiving the intervention access and use of the IAMABLE app for 4 months. People in the comparison group will have access to general web-based health information. We will recruit 50 people, 45 to 75 years, with at least one chronic condition; we will advertise in five communities (Hamilton, Kingston, London, Halifax, Winnipeg) to evaluate feasibility of the study design.\n\nPatients, therapists and app experts will be an expert group to study how the app encourages people to start and continue to use it. We will use patient-reported measures to determine if the people in the IAMABLE group experience better function; quality of life, mobility, participation, self management, pain, health service use, and falls are secondary outcomes. We will measure outcomes at baseline, 4 and 8 months.\n\nResearch Team: Our team is led by researchers with experience in rehabilitation and chronic disease management, including testing technology innovations. Patient advisors will support the project, along with co-investigators with expertise in statistics, technology, and rehabilitation research.\n\nExpected Outcomes: This research has the potential to prove how a web-based app can deliver occupational therapy and physiotherapy to support health and well being for people with chronic conditions. After this study, we plan a larger trial that will focus on effectiveness and address sustained use. IAMABLE will become a resource for people with chronic illnesses to support their independent self-management with rehabilitation strategies.",[25,118,119],"Musculoskeletal Diseases or Conditions","Cardiovascular Diseases",[121,122,123,124,125],"rehabilitation","chronic conditions","self-management","technology","web-based application","2026-02-05",{"date":128,"type":33},"2026-02-06",{"date":130,"type":33},"2025-09-25",{"date":132,"type":21},"2027-03-31",{"name":134,"class":40},"McMaster University",{"id":136,"slug":137,"hasResults":11,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":141,"eligibilityCriteria":142,"healthyVolunteers":11,"sex":17,"minAge":49,"maxAge":143,"enrollmentInfo":144,"targetDuration":4,"studyType":52,"phases":146,"briefSummary":147,"conditions":148,"keywords":151,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":41},"100473300","impact-of-wbc-on-patients-with-metabolic-or-neurological-diseases-or-fibromyalgia-wbc-menefi-100473300","NCT05443100","Impact of WBC on Patients With Metabolic or Neurological Diseases or Fibromyalgia (WBC-MeNeFi)","A Non-randomized Pilot Study of the Impact on Rehabilitation Outcomes of a Course of Whole-body Cryostimulation (WBC) Treatment on Patients With Metabolic or Neurological Diseases or Fibromyalgia","WBC-MeNeFi","Inclusion Criteria:\n\n* both sexes\n* age 18-65 yrs\n* BMI \\> 35 kg\u002Fm2\n\nExclusion Criteria:\n\n* severe psychiatric conditions\n* acute respiratory disease\n* acute cardiovascular disease\n* unstable hypertension\n* cold intolerance\n* claustrophobia\n* pregnancy\n* recent modification of usual drug treatment\n* previous treatment with WBC\n* weight loss in the last 3 months\n* body temperature greater than 37.5°C.","65 Years",{"count":145,"type":21},300,[54],"The purpose of this clinical trial is to investigate on different types of patients the effects of 10 sessions of whole-body cryostimulation (WBC): 1) in patients with obesity (BMI \\> 30), we want to investigate whether WBC increases thermogenesis, basal metabolic rate (BMR), respiratory quotient (which indirectly provides an estimate of energy substrate oxidation), reduces chronic inflammatory status, fatigue and pain, and improves functional abilities and general physical and psychological capacities; 2) in patients diagnosed with fibromyalgia and\u002For osteoarthrytis, we want to investigate the reduction of pain, inflammatory status, increase in functional capacity and general physical and psychological abilities, and improvement in mood; 3) in neurological patients diagnosed with Parkinson's disease, Multiple Sclerosis, and Disimmune Polyneuropathies, the effects of WBC on pain, fatigue, and sleep quality are to be investigated; 4) in normal\u002Foverweight (BMI\\\u003C30 kg\u002Fm2) subjects, the effects of WBC on all parameters described previously for the other protocols are to be investigated. Specifically, for all enrolled subjects, we want to assess blood catecholamine levels, investigate the effects of sympathetic response on body composition, blood pressure, heart rate, lipid profile, and physical performance. Three hundred patients admitted for a rehabilitation program (diet + physiotherapy + exercise) will be non-randomly assigned to either a group following the program (R) or a group additionally receiving ten 2-3 minute WBC sessions at -110°C over two weeks (RWBC).",[149,150,25],"Obesity","Fibromyalgia",[152,149,66,153,154],"Whole-Body cryostimulation","Catecholamines","Thermal stress","2025-08-01",{"date":157,"type":33},"2025-08-04",{"date":159,"type":33},"2019-04-01",{"date":161,"type":21},"2026-12-30",{"name":163,"class":40},"Istituto Auxologico Italiano",{"id":165,"slug":166,"hasResults":11,"nctId":167,"briefTitle":168,"officialTitle":168,"acronym":4,"eligibilityCriteria":169,"healthyVolunteers":16,"sex":17,"minAge":49,"maxAge":4,"enrollmentInfo":170,"targetDuration":172,"studyType":22,"phases":4,"briefSummary":173,"conditions":174,"keywords":187,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":193,"lastUpdatePostDateStruct":194,"startDateStruct":196,"completionDateStruct":198,"leadSponsor":200,"locationsCount":203},"100589754","apple-health-study-100589754","NCT06958523","Apple Health Study","Inclusion Criteria:\n\n* Be at least 18 years old (at least 19 years old in Alabama and Nebraska, at least 21 years old in Puerto Rico);\n* Live in the United States of America;\n* Have an iPhone;\n* Have installed Apple Research app on your iPhone;\n* Be comfortable communicating in written and spoken English;\n* Be willing and able to provide informed consent to participate in the Study.\n\nExclusion Criteria:\n\n* Share your iCloud account, iPhone, or devices that collect health data such as Apple Watch with anyone else, because it could result in sharing another person's health information with the Study, making it challenging for researchers to use your information.",{"count":171,"type":21},500000,"5 Years","The Apple Health Study aims to build a diverse and inclusive group of participants to help researchers advance our understanding of how signals and information collected from apps and devices relate to health and may be used to predict, detect, monitor, and manage changes in health.\n\nTo enroll, US residents who have an iPhone can download the Apple Research app from the App Store and go through the introduction and informed consent for the Apple Health Study. This study is fully remote, and all are invited to enroll if the eligibility criteria are met.\n\nParticipants will be asked to complete tasks and surveys, using their iPhone and Apple Research app which include:\n\n* Selecting the types of data they would like to share with the study such as health and sensor data\n* Completing tasks and surveys including areas such as personal demographic information, personal medical history, family history, and social determinants of health",[175,176,177,178,179,180,181,182,183,25,184,185,186],"Mental Health","Sleep","Exercise","Hormones","Metabolic Health","Hearing","Aging","Lifestyle Factors","Functional Capacity","General Health","Wellbeing","Women's Health",[168,188,189,190,191,192],"Large Scale Digital Study","Digital Biomarkers","Research App","Apple Research App","iPhone","2025-07-24",{"date":195,"type":33},"2025-07-29",{"date":197,"type":33},"2025-02-12",{"date":199,"type":21},"2030-02",{"name":201,"class":202},"Apple Inc.","INDUSTRY",2,{"id":205,"slug":206,"hasResults":11,"nctId":207,"briefTitle":208,"officialTitle":209,"acronym":210,"eligibilityCriteria":211,"healthyVolunteers":11,"sex":17,"minAge":49,"maxAge":4,"enrollmentInfo":212,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":214,"conditions":215,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":217,"startDateStruct":219,"completionDateStruct":221,"leadSponsor":223,"locationsCount":41},"100598347","delirium-incidence-prevention-and-progression-during-acute-intensive-neurological--neurosurgical-rehabilitation-100598347","NCT07070310","DELirium, Incidence, preVEntion and pRogression During Acute Intensive Neurological -Neurosurgical Rehabilitation","DELirium, Incidence, preVEntion and pRogression During Acute Intensive Neurological -Neurosurgical Rehabilitation (Delirinzidenz Und Verlauf während Des Aufenthaltes in Der Neurologisch- Neurochirurgischen Frührehablilitation Der Phase B (NNFR))","DeliVeriNN","Inclusion Criteria:\n\n* Any patient admitted to acute neurological-seurosurgical rehabilitation\n\nExclusion Criteria:\n\n* : patients with level of consciousness of coma or vegetative state",{"count":213,"type":21},210,"In this longitudinal cohort study the incidence of delirium is assessed for all patients being admitted to the acute intensive neurological-neurosurgical rehabilitation over 3 years. Delirium assessment will be performed daily from admission to discharge. Patients will be divided into 3 groups, according to the presentation of delirium on admission, during the course or not any during the stay in acute rehabilitation and compared regarding the treatment and outcome.",[25],"2025-07-17",{"date":218,"type":33},"2025-07-22",{"date":220,"type":21},"2025-08-15",{"date":222,"type":21},"2029-02-15",{"name":224,"class":40},"Heart Centre Rotenburg",{"id":226,"slug":227,"hasResults":11,"nctId":228,"briefTitle":229,"officialTitle":229,"acronym":4,"eligibilityCriteria":230,"healthyVolunteers":11,"sex":17,"minAge":231,"maxAge":4,"enrollmentInfo":232,"targetDuration":4,"studyType":52,"phases":234,"briefSummary":235,"conditions":236,"keywords":244,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":251,"startDateStruct":253,"completionDateStruct":255,"leadSponsor":257,"locationsCount":259},"100597847","neo-reeduc---mixed-reality-for-motor-rehabilitation-a-prospective-multicenter-controlled-randomized-open-study-100597847","NCT07063810","NEO-REEDUC - Mixed Reality for Motor Rehabilitation: a Prospective, Multicenter, Controlled, Randomized, Open Study.","Inclusion Criteria:\n\n\\- Adult patient (18 years old or older) with motor disorders related to a deficit in postural stability (mini-BESTest ≤ 25) which may be associated with a deficit in the use of upper limbs and locomotion, consecutive to : 1) either acquired neurological impairments (ischemic or hemorrhagic stroke in sub-acute or chronic phase, head trauma, benign tumor operated on with complete removal, cerebral anoxia) , or 2) a neurodegenerative affection (Parkinson's disease, Multiple Sclerosis).\n\nOR\n\n* Child or teenager patient (6 to 17 years old) with motor disorders related to a deficit in postural stability (mini-BESTest ≤ 25) which may be associated with a deficit in the use of upper limbs and locomotion, consecutive to 1) either spastic, dyskinetic or ataxic cerebral palsy, or 2) a similar impairment without diagnosis or of another etiology.\n* Patient able to walk with or without technical aids and to perform voluntary upper limb movements.\n* Patient able to understand and follow instructions or adapted communication.\n* Patient having given written informed consent concerning his\u002Fher participation in the protocol OR (for children) whose parents have given their written informed consent.\n* Patient covered by social security.\n\nExclusion Criteria:\n\n* Patient with a severe intellectual disability.\n* Patient with a severe attention deficit disorder.\n* Patient whose epilepsy is not stable.\n* Patient with pain preventing participation in the intended tasks of the protocol.\n* Patient with an illness, medical condition or treatment incompatible with participation in the protocol.\n* Patient with multiple sclerosis with relapse less than 3 months old.\n* Simultaneous participation in other interventional research (1) that may exclude participation in the present study or (2) for which the exclusion period has not ended and whose nature may possibly impact the results of the present research.\n\nIn addition, the vulnerable persons mentioned in Articles L. 1121-5, L.1121-6 and L.1121-8 of the French Public Health Code are excluded from the study:\n\n* Pregnant, nursing or parturient women.\n* Persons deprived of their liberty by judicial or administrative decision, hospitalized without consent or admitted to a health or social institution for purposes other than research.\n* Adults under legal protection or unable to express their consent.","6 Years",{"count":233,"type":21},120,[54],"This study aims to assess the effectiveness of a motor rehabilitation protocol that includes mixed reality activities, compared to conventional rehabilitation, on postural stability in children and adult patients with neurological impairments.",[25,237,238,239,240,241,242,243],"Brain Diseases","Cerebral Palsy","Parkinson Disease (PD)","Multiple Sclerosis","Head Trauma","Ischemic Stroke","Cerebral Anoxia",[245,25,246,247,248,249],"Mixed Reality","Motor Rehabilitation","Postural Stability","Upper Limb","Locomotion","2025-07-02",{"date":252,"type":33},"2025-07-14",{"date":254,"type":21},"2025-07-10",{"date":256,"type":21},"2025-12-31",{"name":258,"class":40},"Slb Pharma",5]